A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder.

CONCLUSIONS:: Patients receiving XR-naltrexone had twice the rate of treatment retention at 6 months compared with those taking oral naltrexone. These results support the use of XR-naltrexone combined with behavioral therapy as an effective treatment for patients seeking opioid withdrawal and nonagonist treatment for preventing relapse to opioid use disorder. PMID: 30336703 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30336703?dopt=Abstract

Source: The American Journal of Psychiatry - October 19, 2018 Category: Psychiatry Authors: Sullivan MA, Bisaga A, Pavlicova M, Carpenter KM, Choi CJ, Mishlen K, Levin FR, Mariani JJ, Nunes EV Tags: Am J Psychiatry Source Type: research

More News: Psychiatry